干扰素阻断CCl4诱导肝纤维化

2012-02-17 MedSci MedSci原创

 日前,南昌大学第二附属医院感染性疾病科张伟、易珍、叶长根等人发表论文,旨在观察干扰素α-2a(interferon alfa-2a,IFNα-2a)对CCl4诱导肝纤维化的作用及影响因素。研究表明,IFNα-2a能够阻断CCl4诱导肝纤维化,其作用效果随IFNα-2a剂量增加而增强。该论文发表在2011年第31期《世界华人消化杂志》上。   研究人员建立了CCl4诱导大鼠肝纤维化模型,SD雌

 日前,南昌大学第二附属医院感染性疾病科张伟、易珍、叶长根等人发表论文,旨在观察干扰素α-2a(interferon alfa-2a,IFNα-2a)对CCl4诱导肝纤维化的作用及影响因素。研究表明,IFNα-2a能够阻断CCl4诱导肝纤维化,其作用效果随IFNα-2a剂量增加而增强。该论文发表在2011年第31期《世界华人消化杂志》上。

  研究人员建立了CCl4诱导大鼠肝纤维化模型,SD雌性大鼠50只,分成5组,每组10只,即生理盐水对照组(A组)、纤维化模型组(B组)、6×104U/kgIFNα-2a干预组(C组)、12×104U/kgIFNα-2a干预组(D组)及6×104U/kgIFNα-2a对照组(E组)。造模8wk时采集血标本及肝组织标本,分别进行肝功能指标ALT、AST、TBIL、TP,肝纤维化指标HA、LN、PCIII检测,及组织病理形态学观察包括HE染色、Masson染色和网状纤维染色。

  结果显示,CCl4腹腔注射成功诱导大鼠肝纤维化模型,表现为汇管区周围纤维化明显,有芒状纤维和纤维间隔形成。血清学检测:B、C、D组ALT、AST、TBiL、HA、LN均明显高于A组;C、D组ALT、AST、TBiL均明显低于B组;D组的上述指标又明显低于C组。组织病理:HE染色、Masson染色和网状纤维染色均显示,C、D组肝组织炎症及肝纤维化程度较B组显著减轻,D组较C组肝纤维化程度更轻,A、E组肝组织未见炎症及纤维化。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1808108, encodeId=e61f18081088f, content=<a href='/topic/show?id=f94d81342e5' target=_blank style='color:#2F92EE;'>#肝纤维#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81342, encryptionId=f94d81342e5, topicName=肝纤维)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sat May 05 07:49:00 CST 2012, time=2012-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1709950, encodeId=6a741e09950ef, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Sat May 05 17:49:00 CST 2012, time=2012-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1490669, encodeId=19b51490669f0, content=<a href='/topic/show?id=c5cb421596' target=_blank style='color:#2F92EE;'>#CCl4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4215, encryptionId=c5cb421596, topicName=CCl4)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=95d48802713, createdName=liuhuangbo, createdTime=Sun Feb 19 09:49:00 CST 2012, time=2012-02-19, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1808108, encodeId=e61f18081088f, content=<a href='/topic/show?id=f94d81342e5' target=_blank style='color:#2F92EE;'>#肝纤维#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81342, encryptionId=f94d81342e5, topicName=肝纤维)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sat May 05 07:49:00 CST 2012, time=2012-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1709950, encodeId=6a741e09950ef, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Sat May 05 17:49:00 CST 2012, time=2012-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1490669, encodeId=19b51490669f0, content=<a href='/topic/show?id=c5cb421596' target=_blank style='color:#2F92EE;'>#CCl4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4215, encryptionId=c5cb421596, topicName=CCl4)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=95d48802713, createdName=liuhuangbo, createdTime=Sun Feb 19 09:49:00 CST 2012, time=2012-02-19, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1808108, encodeId=e61f18081088f, content=<a href='/topic/show?id=f94d81342e5' target=_blank style='color:#2F92EE;'>#肝纤维#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81342, encryptionId=f94d81342e5, topicName=肝纤维)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sat May 05 07:49:00 CST 2012, time=2012-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1709950, encodeId=6a741e09950ef, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Sat May 05 17:49:00 CST 2012, time=2012-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1490669, encodeId=19b51490669f0, content=<a href='/topic/show?id=c5cb421596' target=_blank style='color:#2F92EE;'>#CCl4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4215, encryptionId=c5cb421596, topicName=CCl4)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=95d48802713, createdName=liuhuangbo, createdTime=Sun Feb 19 09:49:00 CST 2012, time=2012-02-19, status=1, ipAttribution=)]
    2012-02-19 liuhuangbo

相关资讯

JGH:α-干扰素联合核苷类似物应用可有效清除乙肝抗原

 MedSci评价:  这个研究结果令人吃惊!其一,疗效十分理想,26.7%(38/147)患者出现HBsAg血清转换(注:S抗原转换难度远远超过E抗原转换,换句话说,比现在所谓的乙肝疫苗强多了),而且随访时间比较长,这是很关键的指标,否则仅仅短期清除乙肝病毒,或实现病毒滴度下降,都无法防止未来继续复发或加重的可能。而长时是随访,而且是S抗原的转换,其疗效是令人欣喜的。不